

Experiment Number: 20209 - 03

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 08/05/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

F_Core_RE

NTP Study Number:

C20209

Lock Date:

08/31/2011

Cage Range:

ALL

Date Range:

ALL

Reasons For Removal:

25021 TSAC

25020 NATD

25019 MSAC

25018 DACC

Removal Date Range:

ALL

Treatment Groups:

Include ALL

Study Gender:

Both

TDMSE Version:

3.0.2.1_001

PWG Approval Date:

NONE

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
----------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	50	50	60
Early Deaths				
Dosing Accident	1	1		1
Moribund Sacrifice	8	7	10	12
Natural Death	4	7	2	12
Survivors				
Terminal Sacrifice	36	35	38	25
Animals Examined Microscopically	49	50	50	50

ALIMENTARY SYSTEM

Esophagus	(49)	(50)	(50)	(50)
Squamous Cell Papilloma			1 (2%)	
Intestine Large, Cecum	(46)	(43)	(49)	(43)
Intestine Large, Colon	(48)	(45)	(50)	(48)
Intestine Large, Rectum	(48)	(46)	(49)	(47)
Intestine Small, Duodenum	(46)	(45)	(49)	(46)
Fibroma	1 (2%)			
Intestine Small, Ileum	(45)	(43)	(49)	(42)
Intestine Small, Jejunum	(45)	(44)	(50)	(46)
Fibroma				1 (2%)
Liver	(49)	(50)	(50)	(50)
Hepatocellular Adenoma	3 (6%)	2 (4%)	4 (8%)	7 (14%)
Hepatocellular Adenoma, Multiple				1 (2%)
Hepatocellular Carcinoma				2 (4%)
Hepatocholangioma				2 (4%)
Mesentery	(12)	(6)	(13)	(10)
Lipoma	1 (8%)			
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(46)	(47)	(50)	(49)
Adenoma	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Adenoma, Multiple			1 (2%)	
Salivary Glands	(46)	(48)	(50)	(50)
Parotid Gland, Adenoma	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Parotid Gland, Carcinoma			1 (2%)	
Stomach, Forestomach	(49)	(50)	(50)	(50)
Fibrosarcoma	1 (2%)			
Leiomyosarcoma				1 (2%)
Squamous Cell Papilloma	1 (2%)			
Squamous Cell Papilloma, Multiple			1 (2%)	
Stomach, Glandular	(48)	(46)	(50)	(49)
Fibrosarcoma	1 (2%)			
Tongue	(0)	(1)	(0)	(0)
Tooth	(1)	(0)	(0)	(0)

CARDIOVASCULAR SYSTEM

Blood Vessel	(0)	(2)	(0)	(0)
Heart	(49)	(50)	(50)	(50)

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(49)	(50)	(49)
Carcinoma	1 (2%)			1 (2%)
Adrenal Medulla	(49)	(48)	(50)	(49)
Pheochromocytoma Benign			1 (2%)	
Pheochromocytoma Complex		1 (2%)		
Pheochromocytoma Malignant	1 (2%)			
Islets, Pancreatic	(49)	(49)	(50)	(50)
Adenoma	4 (8%)	2 (4%)	2 (4%)	1 (2%)
Carcinoma	2 (4%)		1 (2%)	
Parathyroid Gland	(47)	(49)	(50)	(50)
Adenoma	1 (2%)			
Adenoma, Multiple	1 (2%)			
Pituitary Gland	(49)	(49)	(50)	(50)
Craniopharyngioma		1 (2%)		
Ganglioneuroma		1 (2%)		
Glioma Malignant, Metastatic, Brain	1 (2%)		1 (2%)	
Pars Distalis, Adenoma	19 (39%)	12 (24%)	21 (42%)	34 (68%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Pars Distalis, Adenoma, Multiple			1 (2%)	1 (2%)
Pars Intermedia, Adenoma		2 (4%)		
Thyroid Gland	(45)	(45)	(48)	(46)
C-cell, Adenoma	11 (24%)	12 (27%)	10 (21%)	6 (13%)
C-cell, Adenoma, Multiple			1 (2%)	
C-cell, Carcinoma				1 (2%)
Follicular Cell, Adenoma	1 (2%)	3 (7%)	2 (4%)	6 (13%)
Follicular Cell, Carcinoma		2 (4%)	1 (2%)	

GENERAL BODY SYSTEM

Tissue NOS	(3)	(3)	(2)	(1)
Schwannoma Malignant		1 (33%)	1 (50%)	

GENITAL SYSTEM

Epididymis	(49)	(50)	(50)	(50)
Preputial Gland	(49)	(49)	(50)	(50)
Carcinoma	1 (2%)			
Prostate	(49)	(50)	(50)	(50)
Adenoma			1 (2%)	
Seminal Vesicle	(49)	(46)	(50)	(49)
Testes	(49)	(49)	(50)	(50)
Interstitial Cell, Adenoma	2 (4%)	4 (8%)	2 (4%)	4 (8%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(49)	(48)	(50)	(50)
Lymph Node	(2)	(6)	(5)	(6)
Lymph Node, Mandibular	(48)	(49)	(50)	(50)
Lymph Node, Mesenteric	(49)	(49)	(50)	(50)
Hemangioma	1 (2%)		2 (4%)	1 (2%)
Hemangiosarcoma	7 (14%)	2 (4%)	3 (6%)	4 (8%)
Spleen	(47)	(46)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Hemangiosarcoma	1 (2%)			1 (2%)
Thymus	(45)	(49)	(49)	(50)
Thymoma Benign			1 (2%)	
Thymoma Malignant			1 (2%)	

INTEGUMENTARY SYSTEM

Mammary Gland	(33)	(38)	(39)	(41)
Fibroadenoma			3 (8%)	
Fibroma		1 (3%)		
Skin	(49)	(49)	(50)	(50)
Basal Cell Adenoma	1 (2%)	1 (2%)	1 (2%)	
Fibroma	1 (2%)	3 (6%)	1 (2%)	
Fibrosarcoma		1 (2%)		1 (2%)
Hamartoma		1 (2%)		
Hemangiosarcoma		1 (2%)		
Keratoacanthoma	2 (4%)		1 (2%)	
Lipoma			1 (2%)	
Schwannoma Malignant		1 (2%)	1 (2%)	2 (4%)
Squamous Cell Papilloma		1 (2%)		2 (4%)
Pinna, Squamous Cell Papilloma			1 (2%)	

MUSCULOSKELETAL SYSTEM

Bone	(49)	(50)	(50)	(50)
Skeletal Muscle	(1)	(2)	(4)	(0)
Hemangiosarcoma	1 (100%)			

NERVOUS SYSTEM

Brain	(49)	(50)	(50)	(50)
Glioma Malignant	1 (2%)		2 (4%)	
Granular Cell Tumor Benign	1 (2%)			1 (2%)
Meninges, Granular Cell Tumor Benign			1 (2%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Meninges, Hemangioma		1 (2%)		
Peripheral Nerve	(2)	(1)	(3)	(0)
Spinal Cord	(2)	(1)	(3)	(0)

RESPIRATORY SYSTEM

Lung	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma		3 (6%)		
Carcinoma, Metastatic, Adrenal Cortex				1 (2%)
Osteosarcoma, Metastatic, Lung			1 (2%)	
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Thymoma Malignant, Metastatic, Thymus			1 (2%)	
Nose	(49)	(49)	(50)	(50)
Fibrosarcoma				1 (2%)
Respiratory Epithelium, Adenoma		1 (2%)		
Trachea	(49)	(46)	(50)	(49)

SPECIAL SENSES SYSTEM

Eye	(46)	(46)	(50)	(45)
Harderian Gland	(49)	(49)	(50)	(50)
Lacrimal Gland	(0)	(0)	(1)	(2)
Zymbal's Gland	(0)	(0)	(0)	(1)
Carcinoma				1 (100%)

URINARY SYSTEM

Kidney	(49)	(46)	(50)	(50)
Lipoma				1 (2%)
Ureter	(1)	(0)	(0)	(0)
Urinary Bladder	(49)	(48)	(50)	(50)
Leiomyoma				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Experiment Number: 20209 - 03

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Date Report Requested: 08/05/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
<hr/>				
SYSTEMIC LESIONS				
Multiple Organ	*(49)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		2 (4%)	1 (2%)	
Leukemia	1 (2%)			
Lymphoma Malignant		4 (8%)	1 (2%)	
Mesothelioma Malignant		1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Experiment Number: 20209 - 03

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Date Report Requested: 08/05/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
----------------------	---------	---------	----------	----------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	36	39	44	47
Total Primary Neoplasms	71	68	76	88
Total Animals with Benign Neoplasms	33	34	40	45
Total Benign Neoplasms	53	52	63	72
Total Animals with Malignant Neoplasms	13	14	10	12
Total Malignant Neoplasms	18	16	13	16
Total Animals with Metastatic Neoplasms	1	1	3	1
Total Metastatic Neoplasms	1	1	3	1
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
------------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	50	50	60
Early Deaths				
Dosing Accident	2	1		
Moribund Sacrifice	8	10	13	11
Natural Death	3		4	10
Survivors				
Natural Death	1			
Terminal Sacrifice	36	39	33	28
Animals Examined Microscopically	50	50	50	49

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Intestine Large, Cecum	(48)	(49)	(47)	(40)
Intestine Large, Colon	(48)	(49)	(50)	(46)
Carcinoma, Metastatic, Pancreas				1 (2%)
Intestine Large, Rectum	(49)	(49)	(49)	(45)
Intestine Small, Duodenum	(47)	(49)	(47)	(42)
Leiomyosarcoma		1 (2%)		
Intestine Small, Ileum	(47)	(49)	(48)	(41)
Intestine Small, Jejunum	(46)	(49)	(47)	(42)
Leiomyoma		1 (2%)	1 (2%)	
Liver	(50)	(49)	(50)	(47)
Adenocarcinoma, Metastatic, Uterus			2 (4%)	
Carcinoma, Metastatic, Pancreas				1 (2%)
Cholangiocarcinoma				1 (2%)
Cholangiocarcinoma, Multiple				1 (2%)
Hepatocellular Adenoma	2 (4%)	2 (4%)	6 (12%)	8 (17%)
Hepatocellular Adenoma, Multiple	1 (2%)		2 (4%)	8 (17%)
Hepatocellular Carcinoma			1 (2%)	3 (6%)
Hepatocellular Carcinoma, Multiple				3 (6%)
Hepatocholangiocarcinoma				1 (2%)
Hepatocholangioma				5 (11%)
Hepatocholangioma, Multiple				3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Mesentery	(10)	(7)	(9)	(6)
Adenocarcinoma, Metastatic, Uterus			3 (33%)	
Granulosa Cell Tumor Malignant, Metastatic, Ovary	1 (10%)			
Schwannoma Malignant			1 (11%)	
Oral Mucosa	(0)	(0)	(1)	(1)
Squamous Cell Carcinoma			1 (100%)	
Pancreas	(50)	(49)	(49)	(47)
Adenocarcinoma, Metastatic, Uterus Carcinoma			3 (6%)	1 (2%)
Salivary Glands	(50)	(50)	(49)	(45)
Parotid Gland, Adenocarcinoma				1 (2%)
Sublingual Gland, Adenocarcinoma	1 (2%)			
Stomach, Forestomach	(50)	(49)	(50)	(48)
Adenocarcinoma, Metastatic, Uterus			2 (4%)	
Squamous Cell Papilloma			1 (2%)	
Stomach, Glandular	(49)	(49)	(50)	(46)
Adenocarcinoma, Metastatic, Uterus Carcinoma, Metastatic, Pancreas			1 (2%)	1 (2%)
Tooth	(1)	(0)	(0)	(0)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(1)	(0)	(3)	(3)
Heart	(50)	(50)	(50)	(48)
Endocardium, Schwannoma Benign		1 (2%)		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(50)	(46)
Adenocarcinoma, Metastatic, Uterus			2 (4%)	
Adenoma	1 (2%)			
Adrenal Medulla	(50)	(50)	(50)	(47)
Pheochromocytoma Benign	1 (2%)	1 (2%)	1 (2%)	
Pheochromocytoma Complex	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Pheochromocytoma Malignant			1 (2%)	
Islets, Pancreatic	(50)	(49)	(49)	(47)
Adenoma		1 (2%)		
Parathyroid Gland	(49)	(47)	(49)	(46)
Adenoma	1 (2%)	1 (2%)		
Pituitary Gland	(50)	(49)	(50)	(47)
Pars Distalis, Adenoma	21 (42%)	20 (41%)	23 (46%)	20 (43%)
Pars Distalis, Adenoma, Multiple	2 (4%)			1 (2%)
Pars Intermedia, Adenoma	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Thyroid Gland	(45)	(49)	(47)	(42)
C-cell, Adenoma	6 (13%)	3 (6%)	7 (15%)	2 (5%)
C-cell, Adenoma, Multiple	1 (2%)	3 (6%)	3 (6%)	2 (5%)
Follicular Cell, Adenoma	1 (2%)	3 (6%)	3 (6%)	1 (2%)

GENERAL BODY SYSTEM

Tissue NOS	(3)	(2)	(4)	(2)
Adenocarcinoma, Metastatic, Uterus			2 (50%)	
Abdominal, Carcinoma, Metastatic, Pancreas				1 (50%)

GENITAL SYSTEM

Clitoral Gland	(49)	(49)	(50)	(47)
Ovary	(50)	(49)	(50)	(46)
Adenocarcinoma, Metastatic, Uterus			1 (2%)	
Carcinoma, Metastatic, Pancreas				1 (2%)
Cystadenoma		1 (2%)	1 (2%)	2 (4%)
Granulosa Cell Tumor Benign	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Granulosa Cell Tumor Malignant	1 (2%)			
Leiomyosarcoma		1 (2%)		
Luteoma		1 (2%)		
Schwannoma Malignant, Metastatic, Mesentery			1 (2%)	
Uterus	(50)	(49)	(50)	(47)
Adenocarcinoma		1 (2%)	3 (6%)	2 (4%)
Adenocarcinoma, Multiple	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Adenoma	1 (2%)		1 (2%)	
Carcinoma, Metastatic, Pancreas				1 (2%)
Granular Cell Tumor Benign			1 (2%)	
Leiomyoma		1 (2%)		
Malignant Mixed Mullerian Tumor	1 (2%)			
Polyp Stromal	3 (6%)	5 (10%)	6 (12%)	5 (11%)
Polyp Stromal, Multiple		1 (2%)	1 (2%)	
Sarcoma Stromal			1 (2%)	
Schwannoma Malignant			2 (4%)	1 (2%)
Cervix, Granular Cell Tumor Benign	1 (2%)			
Cervix, Polyp Stromal				1 (2%)
Cervix, Schwannoma Malignant	1 (2%)			
Vagina	(1)	(1)	(2)	(2)
Granular Cell Tumor Benign		1 (100%)		
Granular Cell Tumor Benign, Multiple				1 (50%)
Polyp, Multiple				1 (50%)
Sarcoma Stromal, Metastatic, Uterus			1 (50%)	
Schwannoma Malignant, Metastatic, Uterus			1 (50%)	

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(46)
Lymph Node	(10)	(5)	(6)	(9)
Mediastinal, Adenocarcinoma, Metastatic, Uterus			1 (17%)	
Lymph Node, Mandibular	(50)	(50)	(50)	(48)
Adenocarcinoma, Metastatic, Salivary Glands				1 (2%)
Lymph Node, Mesenteric	(50)	(49)	(50)	(46)
Hemangiosarcoma	2 (4%)			
Spleen	(50)	(49)	(50)	(45)
Adenocarcinoma, Metastatic, Uterus			1 (2%)	
Thymus	(50)	(49)	(48)	(46)
Thymoma Benign				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(49)	(50)	(48)
Carcinoma	1 (2%)	1 (2%)	2 (4%)	3 (6%)
Carcinoma, Multiple				1 (2%)
Fibroadenoma	8 (16%)	7 (14%)	10 (20%)	6 (13%)
Fibroadenoma, Multiple	1 (2%)	3 (6%)	2 (4%)	3 (6%)
Skin	(50)	(50)	(50)	(49)
Basal Cell Adenoma	1 (2%)			
Osteosarcoma, Metastatic, Bone	1 (2%)			
Schwannoma Malignant		1 (2%)		
Squamous Cell Papilloma			1 (2%)	2 (4%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(49)
Femur, Osteosarcoma	1 (2%)			
Skeletal Muscle	(1)	(0)	(0)	(0)
Granulosa Cell Tumor Malignant, Metastatic, Ovary	1 (100%)			

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(49)
Glioma Malignant			1 (2%)	
Peripheral Nerve	(0)	(0)	(1)	(0)

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(49)
Adenocarcinoma, Metastatic, Uterus			2 (4%)	1 (2%)
Carcinoma, Metastatic, Pancreas				1 (2%)
Malignant Mixed Mullerian Tumor, Metastatic, Uterus	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Schwannoma Malignant, Metastatic, Uterus			1 (2%)	
Nose	(50)	(50)	(50)	(47)
Chondroma	1 (2%)			
Trachea	(47)	(50)	(50)	(47)

SPECIAL SENSES SYSTEM

Ear	(1)	(0)	(0)	(0)
Eye	(50)	(49)	(47)	(45)
Harderian Gland	(49)	(50)	(50)	(49)

URINARY SYSTEM

Kidney	(50)	(50)	(49)	(47)
Ureter	(1)	(0)	(0)	(1)
Urinary Bladder	(50)	(49)	(49)	(45)
Adenocarcinoma, Metastatic, Uterus			2 (4%)	

SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(49)
Histiocytic Sarcoma			1 (2%)	1 (2%)
Leukemia Granulocytic			2 (4%)	
Lymphoma Malignant		3 (6%)		

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Experiment Number: 20209 - 03

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Date Report Requested: 08/05/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 10:18:12

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 08/26/08 / 08/26/08

Species/Strain: RATS/Wistar Han

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
------------------------	---------	---------	----------	----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	40	38	46	44
Total Primary Neoplasms	65	68	90	94
Total Animals with Benign Neoplasms	37	35	41	43
Total Benign Neoplasms	55	60	73	75
Total Animals with Malignant Neoplasms	10	8	13	16
Total Malignant Neoplasms	10	8	17	19
Total Animals with Metastatic Neoplasms	3		7	3
Total Metastatic Neoplasms	4		26	9
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors